Publications by authors named "K Karberg"
Background: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence treatment patterns for rheumatoid arthritis (RA) drugs, but little is known about the impact of these recommendations in routine clinical care.
Methods: We retrospectively analyzed the German RHADAR rheumatology database for adult patients with RA and documentation of a new therapy with a JAKi, tumor necrosis factor inhibitor (TNFi), or interleukin-6 receptor inhibitor (IL-6Ri). Data were grouped into half-yearly intervals from quarter (Q)2/2020 to Q3/2023.
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
Rheumatol Int
October 2024
Article Synopsis
- Janus kinase inhibitors (JAKi) have recently been approved alongside tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) as treatment options for axial spondyloarthritis (axSpA), yet their real-world drug survival is under-studied.
- A retrospective analysis of 1,222 axSpA patients, focusing on treatment initiation timing from January 2015 to October 2023, reveals median drug survival rates of 31 months for TNFi, 25 months for IL-17i, and 18 months for JAKi.
- Higher discontinuation rates were seen for JAKi and IL-17i compared to TNFi, with
Telemedicine applications present virtually limitless prospects for innovating and enhancing established and new models of patient care in the field of Internal Medicine. Although there is a wide range of innovative technological solutions in Europe, there are overarching elements associated with such technologies when applied to the practices of Internal Medicine specialists. The European Federation of Internal Medicine (EFIM) strongly advocates for active leadership and influence from the Internal Medicine societies and specialist physicians across Europe in the development and application of telemedicine and digital technologies in healthcare.
View Article and Find Full Text PDFDrug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
Front Immunol
June 2024
Article Synopsis
- Treatment options for psoriatic arthritis have expanded to include various biologic DMARDs and Janus kinase inhibitors, but real-world data on their persistence in patients is limited.
- A study analyzed 1352 prescriptions and found that the 5-year survival rates were highest for IL-17 inhibitors (67.8%) and lowest for IL-12/23 inhibitors (46.0%), with JAKi showing a higher likelihood of discontinuation.
- The findings suggest that patients in Germany may stick with TNFi and IL-17i longer than IL-12/23i or JAKi, potentially influenced by disease severity and other health conditions like osteoarthritis.
In the National database (NDB) of the German regional collaborative arthritis centres, annual data on the rheumatological care of patients with inflammatory rheumatic diseases have been collected since 1993. This first annual report presents current cross-sectional data on medication and patient-reported outcomes gathered in 2022.
View Article and Find Full Text PDF